SECOND PRIMARY MALIGNANCIES AFTER BENDAMUSTINE-RITUXIMAB IN INDOLENT LYMPHOMAS: INCREASED RISK IN WALDENSTRÖM MACROGLOBULINEMIA? A COMPARATIVE ANALYSIS WITH FOLLICULAR LYMPHOMA FROM FIL FOLL12 TRIAL (SIE 2026) - Oct 6, 2026 - Abstract #DP055; Pres time: Sep 21, 2026; 07:00 PM - 08:00 PM; Location: AREA POSTER; "Deaths related to SPMs were propor- tionally more frequent in WM (8/31, 25.8%) than in FL (10/64, 15.6%).In conclusion, WM pts treated with BR ap- pear to have a higher risk of developing SPMs compared to FL, with a relevant impact on mortality. These findings sup- port structured long-term surveillance in WM and prospec- tive studies to clarify the drivers of increased oncologic risk, including treatment, disease biology, and patient susceptibil- ity."
Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Colorectal Cancer • Endocrine Cancer • Esophageal Cancer • Follicular Lymphoma • Germ Cell Tumors • Hematological Malignancies • Indolent Lymphoma • Leiomyosarcoma • Leukemia • Liver Cancer • Lymphoma • Lymphoplasmacytic Lymphoma • Melanoma • Myelodysplastic Syndrome • Neuroendocrine Neoplasm • Oncology • Renal Cell Carcinoma • Sarcoma • Solid Tumor • Testicular Seminoma • Thyroid Gland Carcinoma • Waldenstrom Macroglobulinemia
|
|
F. Autore1; Am. Frustaci2; A. Conconi3; G. Benevolo4; N. Danesin5; D. Giannarelli1; I. Del Giudice6; A. Anastasia7; C. Boccomini8; R. Rizzi9; M. Nicolosi8; E. Cencini10; R. Pasquale11; C. Conticello12; S. Steffanoni13; M. Bullo14; D. Marino15; M. Gentile16; G. D'Uva4; I. Innocenti1; L. Stirparo1; J. Olivieri11; F. Piazza5; S. Ferrero4; L. Arcaini17; A. Tedeschi2; L. Laurenti1; S. Luminari18
|